TC
Tianle Chen
Alzheimer DiseaseAlzheimer’s diseaseamyloid betaaducanumabAducanumabAlzheimer's diseaseAntibodies, Monoclonal, HumanizedAmyloid beta-Peptidesbiomarkerpositron emission tomography
On Valency
published · living versionsW_8yystk3x·v1 · currentpublished
Beyond the Teacher: Understanding and Preserving Distillation Overshoot in Agentic On-Policy Distillation
with Jike Zhong, Ming Li, Yuxiang Lai, Xi Xiao +7
1 version
Preprints & journals
23 papers in the corpus · 2007–2026A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease.41478826 · Chen, Tianle, Hutchison, R Matthew, Rubel, Carrie et al.2026 · 2 citationsThe journal of prevention of Alzheimer's disease. 2026:100458
Some Modalities are More Equal Than Others: Decoding and Architecting Multimodal Integration in MLLMs2511.22826v2 · Tianle Chen, Chaitanya Chakka, Arjun Reddy Akula et al.2025 · 0 citationsarXiv
Harnessing Greater Statistical Power: Comprehensive Evaluation of Disease Modifying Treatment Effects Across All or Multiple Post-Baseline Visits Compared to the Last Visit for Alzheimer's Disease Clinical Trials.40034790 · Wang, Guoqiao, Chen, Tianle, O'Gorman, John et al.2026 · 2 citationsmedRxiv : the preprint server for health sciences. 2025
Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.38567735 · Chen, Tianle, O'Gorman, John, Castrillo-Viguera, Carmen et al.2024 · 34 citationsAlzheimer's & dementia : the journal of the Alzheimer's Association. 2024;20(5):3406-3415
Letter to the Editor: Update to: Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.39044530 · Rubel, C, Chen, T, Dent, G2024 · 2 citationsThe journal of prevention of Alzheimer's disease. 2024;11(4):1178-1179
A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease.39350368 · Chen, T, Hutchison, R M, Rubel, C et al.2024 · 10 citationsThe journal of prevention of Alzheimer's disease. 2024;11(5):1228-1240
Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease.39350371 · Toda, Y, Iwatsubo, T, Nakamura, Y et al.2024 · 10 citationsThe journal of prevention of Alzheimer's disease. 2024;11(5):1260-1269
CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab.36795603 · Nisenbaum, Laura, Martone, Robert, Chen, Tianle et al.2023 · 14 citationsAlzheimer's & dementia : the journal of the Alzheimer's Association. 2023;19(8):3379-3388
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.36946443 · Mallinckrodt, C, Tian, Y, Aisen, P S et al.2023 · 25 citationsThe journal of prevention of Alzheimer's disease. 2023;10(2):171-177
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.35542991 · Budd Haeberlein, S, Aisen, P S, Barkhof, F et al.2022 · 1,358 citationsThe journal of prevention of Alzheimer's disease. 2022;9(2):197-210
Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab.29777003 · Chiao, Ping, Bedell, Barry J, Avants, Brian et al.2019 · 63 citationsJournal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019;60(1):100-106
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.28640269 · Sevigny, Jeff, Chiao, Ping, Bussière, Thierry et al.2019 · 83 citationsNature. 2017;546(7659):564
Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.29181491 · Budd Haeberlein, S, O'Gorman, J, Chiao, P et al.2018 · 87 citationsThe journal of prevention of Alzheimer's disease. 2017;4(4):255-263
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.27582220 · Sevigny, Jeff, Chiao, Ping, Bussière, Thierry et al.2016 · 3,043 citationsNature. 2016;537(7618):50-6
Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial.26885819 · Sevigny, Jeff, Suhy, Joyce, Chiao, Ping et al.2016 · 114 citationsAlzheimer disease and associated disorders. 2016;30(1):1-7
Support Vector Hazards Machine: A Counting Process Framework for Learning Risk Scores for Censored Outcomes.28066157 · Wang, Yuanjia, Chen, Tianle, Zeng, Donglin2023 · 7 citationsJournal of machine learning research : JMLR. 2016;17
Multiple kernel learning with random effects for predicting longitudinal outcomes and data integration.26177419 · Chen, Tianle, Zeng, Donglin, Wang, Yuanjia2016 · 19 citationsBiometrics. 2015;71(4):918-28
Predicting cumulative risk of disease onset by redistributing weights.25847392 · Chen, Tianle, Ma, Yanyuan, Wang, Yuanjia2016 · 0 citationsStatistics in medicine. 2015;34(16):2427-43
Targeted Local Support Vector Machine for Age-Dependent Classification.25284918 · Chen, Tianle, Wang, Yuanjia, Chen, Huaihou et al.2021 · 5 citationsJournal of the American Statistical Association. 2014;109(507):1174-1187
Predicting Disease Onset from Mutation Status Using Proband and Relative Data with Applications to Huntington's Disease.23476655 · Chen, Tianle, Wang, Yuanjia, Ma, Yanyuan et al.2021 · 10 citationsJournal of probability and statistics. 2012;2012
Growth of a scientific community of practice public health services and systems research.21665071 · Merrill, Jacqueline A, Keeling, Jonathan W, Wilson, Rosalind V et al.2011 · 10 citationsAmerican journal of preventive medicine. 2011;41(1):100-4
Pros and cons of prostate cancer screening: associations with screening knowledge and attitudes among urban African American men.20355346 · Davis, Stacy N, Diefenbach, Michael A, Valdimarsdottir, Heiddis et al.2010 · 22 citationsJournal of the National Medical Association. 2010;102(3):174-82
Global gene expression analysis of the shoot apical meristem of maize (Zea mays L.).17764504 · Ohtsu, Kazuhiro, Smith, Marianne B, Emrich, Scott J et al.2008 · 145 citationsThe Plant journal : for cell and molecular biology. 2007;52(3):391-404
Career total: 63 works. 23 are in this corpus.
Profile built from the corpus for this byline.
Author records are still filling in while the Hub is in alpha. If this is your page, you'll be able to claim it soon. Spot a mistake? Tell us.